Cardiovascular autonomic neuropathy contributes to sleep apnea in young and lean type 1 diabetes mellitus patients

Carolina Castro Porto Silva Janovsky1*, Luiz Clemente de Souza Pereira Rolim1, João Roberto de Sá1, Dalva Poyares2, Sergio Tufik2, Ademir Baptista Silva3 and Sergio Atala Dib1

1 Endocrinology and Diabetes Division, Medicine Department, Universidade Federal de São Paulo, São Paulo, Brazil
2 Sleep Medicine Division, Psychiatry Department, Universidade Federal de São Paulo, São Paulo, Brazil
3 Clinical Neurology Division, Neurology and Neurosurgery Department, Universidade Federal de São Paulo, São Paulo, Brazil

INTRODUCTION

Obstructive sleep apnea (OSA) in diabetic patients has been frequently explained by obesity associated with type 2 diabetes (T2DM) (1). However, little is known about the presence of OSA in young, non-obese individuals with type-1 diabetes (T1DM).

During sleep, respiratory function is partially controlled by the autonomic nervous system (ANS). When this system is impaired, dysautonomy may favor the occurrence of OSA in diabetic patients regardless of age and weight.

Exploring the relationship between sleep apnea and autonomic dysfunction is an important topic of interest because it impacts both patient care and quality of life (4). Therefore, the knowledge of the prevalence of OSA in T1DM and its relationship with CAN could have a high clinical benefit.

The aim of this study was to compare the prevalence of OSA in young, lean T1DM, with and without CAN.

RESEARCH DESIGN AND METHODS

We recruited 20 adult T1DM patients with a >5-year diagnosis with intensive insulin therapy from the Diabetes Center of the Federal University of São Paulo. The control group (C group) consisted of 22 healthy individuals, medical students from the Federal University of São Paulo; all were young and none were obese (BMI <25 kg/m²). The subjects were enrolled after they signed informed consent forms. The protocol was approved by the local ethical committee and was in accordance with the Helsinki Declaration. All enrolled individuals completed the study.

The most recent clinical and laboratory data were taken from the patients’ Diabetes Center file. Patients with clinical nephropathy or non-treated thyroid disease were excluded from the analysis.

Autonomic neuropathy was assessed by the following standard protocol of cardiovascular autonomic reflex tests (CARTs) (5) with continuous monitoring of electrocardiography: (1) heart rate variations with deep breathing; (2) heart rate response to the Valsalva maneuver; (3) heart rate changes when standing from the lying position; and (4) postural fall in systolic BP (6). A physician specialized in diabetic neuropathy performed the exam in these controls individuals and diabetic patients at the Diabetes Center early in the morning. The controls and the patients have fasted for the 8 h prior to testing and were not hypoglycemic. The presence of CAN was defined by at least two positive tests (out of four). Additionally, all subjects were sent to the sleep lab (UNIFESP Sleep Institute) at 8 p.m. to perform the polysomnography exam.
Table 1 | Clinical, metabolic characteristics, and polysomnography parameters in controls and T1DM patients with (CAN+) and without (CAN−) cardiovascular autonomic neuropathy.

|                  | Control group | T1DM CAN (−) | T1DM CAN (+) | p         |
|------------------|---------------|--------------|--------------|-----------|
| Age (years)      | 23.2 ± 3.9    | 27.0 ± 8.2   | 32.7 ± 6.8   | NS        |
| BMI (kg/m²)      | 21.8 ± 2.14   | 22.1 ± 1.8   | 24.5 ± 2.5   | NS        |
| HbA1c (%)        | N/A           | 75 ± 1.7     | 9 ± 2.3      | NS        |
| Time from diabetes diagnosis (years) | N/A | 16.7 ± 78   | 14.8 ± 5.3   | NS        |
| ESS > 9 (% of patients) | 18.8 | 45.4 | 55.5 | Control vs. T1DM, 0.002; CAN(−) vs. CAN(+), 0.03 |
| Total sleep time (min) | 415.9 ± 38.8   | 379.0 ± 50.8 | 359.1 ± 51.1 | NS        |
| Sleep Efficiency (%) | 85.0 ± 9.4   | 88.4 ± 5.5   | 80.2 ± 10.7  | Control vs. T1DM, 0.002; CAN(−) vs. CAN(+), 0.04 |
| Microarousals (events/h) | 7.0 ± 5.0   | 7.7 ± 4.1    | 12.4 ± 5.1   | Control vs. T1DM, 0.0003; CAN(−) vs. CAN(+), 0.03 |
| REM (%)          | 15.9 ± 5.4    | 173 ± 2.8    | 175 ± 8.0    | NS        |
| SWS4 (%)         | 20.3 ± 7.2    | 22.6 ± 6.8   | 18.9 ± 9.6   | NS        |
| OSAH1p (events/h) | 2.0 ± 2.3   | 3.2 ± 1.9    | 6.4 ± 4.6    | Control vs. T1DM, NS; CAN(−) vs. CAN(+), 0.04 |
| OSAH1p (% of patients) | 4.5 | 23.0 | 66.6 | Control vs. T1DM, 0.006; CAN(−) vs. CAN(+), 0.01 |
| Desaturation (%) | 4.2 ± 0.9     | 2.9 ± 2.3    | 4.3 ± 2.5    | NS        |

Values are expressed as the mean and standard deviation (SD). Bold font indicates statistically significant results.
REM, rapid-eye movement.
SWS, slow wave sleep (stages 3 and 4).
OSAH1p, obstructive sleep apnea/hypopnea index.
N/A, not available; NS, non-significant.

There, they were first tested with the Epworth Somnolence Score (ESS), a score that subjectively measures the excessive daytime sleepiness by asking questions about the probability of sleeping in some situations, i.e., watching TV, driving, or waiting at the doctor’s office. The ESS was considered positive for scores as high as nine points (7).

Afterwards, the polysomnography (ALICE – Phillips) was performed according to the recommendations of the American Sleep Disorders Association (7). The exam was performed at night, from 10 p.m. to 6 a.m., and the patients had to avoid caffeine and alcohol 48 h before the exam. The medication was maintained as usual, except for psychotropic drugs, which were withdrawn 1 week before the exam. Sleep data were analyzed with consideration for the sleep latency, duration, stages and efficiency, periodic movements of the limbs, snoring, microarousals, obstructive apnea/hypopnea index (OSAH1), and saturation. Continuous electrocardiogram and electroencephalogram were used to monitor the subjects, and cameras with infrared light were used to monitor the patient.

Obstructive sleep apnea was defined by an OSAH1 that was higher than 5/h in the polysomnography. We defined hypopnea as an airflow reduction of 30–50% and apnea as >50%. The microarousal index was considered positive when there were more than 14 events/h (7). The statistical analysis was performed by Pearson chi-square for categorical variables and t-tests for continuous variables. A univariate regression test was performed to confirm the homogeneity of the groups. A p-value <0.05 was considered significant (Statistic 7.0 Stat Soft Inc.; Tulsa, OK, USA).

RESULTS
We evaluated 22 non-obese young adults without diabetes (Control group = C) and 20 patients with type 1 diabetes (T1DM) who were also young and non-obese. We divided the T1DM patients into two groups, positive [n = 9 (CAN+)] and negative [n = 11; (CAN−)], according to the CAN protocol results (6, 8, 9).

Comparing the diabetic group with the control group, the prevalence of excessive daytime somnolence, measured by the EES, and sleep apnea was significantly higher in the diabetic group (p = 0.006 and p = 0.002, respectively).

The comparisons of clinical, glycemic control, and polysomnography variables between controls, CAN (+) and CAN (−) T1DM patients are shown in Table 1.

According to a univariate regression test, there was no difference in the age of the studied groups.

The mean HbA1c level and the treatment schedule of these patients were similar to the general population of T1DM patients in São Paulo Federal University Diabetes Center.
DISCUSSION
This is the first study reporting that young, lean, and long-duration T1DM patients have more OSA than healthy age- and BMI-matched individuals.

Additionally, in lean and young T1DM patients, those with CAN have a higher prevalence of OSA, excessive daytime somnolence, and worse sleep architecture.

Because OSA is an uncommon finding in young and lean individuals, this high prevalence in type 1 diabetes patients, with this profile, suggests that CAN may play an important role in its pathophysiology.

Cardiovascular autonomic neuropathy may be concomitant with the damage of vagal reflexes, affecting the upper airway integrity and leading, at last, to sleep apnea (10).

During normal sleep, in contrast to during wakefulness, the parasympathetic ANS controls slow wave sleep (non-REM), reducing sympathetic nerve traffic, heart rate, and blood pressure (10). On the other hand, the sympathetic ANS is responsible for the rapid-eye movement (REM) phase, resulting in intermittent and brief surges in the blood pressure and heart rate. These organized responses to normal sleep are completely disrupted in patients with OSA (2, 3, 10). OSA and hypopneas commonly result in arousals, hypoxemia, and hypercapnia, which are associated with an increase in sympathetic activity and a decrease in the parasympathetic activity, leading not only to higher cardiovascular risk but also to higher oxidative stress and potentially CAN impairment (10–18).

Additionally, because OSA can aggravate and amplify oxidative stress and, ultimately, CAN, the former could contribute to the latter, resulting in a vicious circle. It is important to keep in mind that prospective studies with a larger group of type 1 diabetic patients are needed to determine the mutual relationship between OSA and CAN. However, we can at least speculate that the positive impact of CPAP treatment on oxidative stress and CAN could have significant implications in the prognosis and quality of life of these patients.

Furthermore, we can hypothesize that because diabetes and OSA are associated with increased cardiovascular morbidity and mortality, the presence of both conditions results in additive or even synergistic health risks (19, 20).

To evaluate the prevalence of sleep apnea, we performed a polysomnography, the gold standard test for diagnosis (7). We to evaluate the prevalence of sleep apnea, we performed a polysomnography, the gold standard test for diagnosis (7). We know that the first night effect might impact our results. However, all patients followed the same protocol and so the results could be comparable.

Recently, studies have shown that the OSA per se may impact the levels of HbA1c and the quality of life (4, 21, 22). This fact makes the early diagnosis and treatment of this sleep disturbance even more important for avoiding further chronic diabetes complications in these patients.

However, long-term follow-up studies, as we discussed previously, are needed to determine whether OSA increases the predictive power of autonomic neuropathy for cardiovascular mortality. Spectral analysis during the sleep could help us determine whether these patients are more likely to have sympathetic or parasympathetic damage during sleep.

In conclusion, OSA may be related to the presence of CAN in young and lean T1DM patients.

AUTHOR CONTRIBUTIONS
Carolina Castro Porto Silva Janovsky collected the data and wrote the manuscript. Luiz Clemente de Souza Pereira Rolim collected the data, contributed to the discussion, and reviewed the manuscript. João Roberto de Sa contributed to the discussion and reviewed the manuscript. Dalva Poyares collected data and contributed to the statistical analysis. Sergio Tufik collected data. Ademir Baptista Silva collected data, contributed to the discussion, and reviewed the manuscript. Sergio Atala Dib wrote and reviewed the manuscript.

REFERENCES
1. Foster GD, Sanders MH, Millman R, Zammitti G, Borradaile KE, Newman AB, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care (2009) 32:1017–9. doi:10.2337/dc08-1776
2. Guilleminault C, Briskin JG, Greenfield MS, Silvestri R. The impact of autonomic nervous system dysfunction on breathing during sleep. Sleep (1981) 4:263–78.
3. Catterall JR, Calverley PMA, Ewing DJ, Shapiro CM, Clarke BE, Douglas NJ. Breathing, sleep, and diabetic autonomic neuropathy. Diabetes (1984) 33:1025–7. doi:10.2337/diabetes.33.11.1025
4. Perfect MM, Patel PG, Scott RE, Wheeler MD, Patel C, Griffin K, et al. Sleep, glucose, and daytime functioning in youth with type 1 diabetes. Sleep (2012) 35(1):81–8. doi:10.5665/sleep.1590
5. Rolim LC, de Souza JST, Dib SA. Tests for early diagnosis of cardiovascular autonomic neuropathy; critical analysis and relevance. Front Endocrinol (2013) 4:173. doi:10.3389/fendo.2013.00173
6. Ewing DJ, Clark BE. Diagnosis and management of diabetic autonomic neuropathy. BMJ (1982) 285:916–8. doi:10.1136/bmj.285.6346.916
7. American Sleep Disorders Standards of Practice Committee. Practice parameters for the indications for polysomnography and related procedures. Sleep (1997) 20:406–22.
8. Freeman R. Autonomic peripheral neuropathy. Lancet (2005) 365:1259–70. doi:10.1016/S0140-6736(05)74815-7
9. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care (2005) 28:956–62. doi:10.2337/diacare.28.4.956
10. Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 4th ed. Philadelphia, PA: Elsevier Saunders (2005).
11. Neumann C, Martinez D, Schmid H. Nocturnal oxygen desaturation in diabetic patients with severe autonomic neuropathy. Diabetes Res Clin Pract (1995) 28:97–102.
12. Ficker JH, Dertinger SH, Siegfried W, König HJ, Pentz M, Sailer D, et al. Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. Eur Respir J (1998) 11:14–9. doi:10.1183/09031936.98.11010014
13. Tantucci C, Scianti L, Bottini P, Dottorini ML, Puxeddu E, Casucci G, et al. Influence of autonomic neuropathy of different severity on the hypercapnic drive to breathing in diabetic patients. Chest (1997) 112:2145–53. doi:10.1378/chest.112.1.1145
14. Taherani AA, Ali A, Raymond NT, Begum S, Dubb K, Mughal S, et al. Obstructive sleep apnea and diabetic neuropathy. Am J Respir Crit Care Med (2012) 186(5):534–41. doi:10.1164/rccm.201112-2135OC
15. Bottini P, Dottorini ML, Cordoni MC, Casucci G, Tantucci C. Sleep-disordered breathing in nonobese diabetic subjects with autonomic neuropathy. Eur Respir J (2003) 22(6):654–60. doi:10.1183/09031936.03.0070402
16. Keller T, Hader C, De Zeeuw J, Rasche K. Obstructive sleep apnea syndrome: the effect of diabetes and autonomic neuropathy. J Physiol Pharmacol (2007) 58(Suppl 5(Pt 1)):313–8.
17. Mondini S, Guilleminault C. Abnormal breathing patterns during sleep in diabetes. Ann Neurol (1985) 17:391–5. doi:10.1002/ana.410170415
18. Rees PJ, Prior JG, Cochrane GM, Clark TJ. Sleep apnoea in diabetic patients with autonomic neuropathy. J R Soc Med (1981) 74:192–5.
Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 31 March 2014; accepted: 07 July 2014; published online: 11 August 2014.
Citation: Janovsky CCPS, Rolim LCSP, Sá JR, Poyares D, Tufik S, Silva AB and Dib SA (2014) Cardiovascular autonomic neuropathy contributes to sleep apnea in young and lean type 1 diabetes mellitus patients. Front. Endocrinol. 5:119. doi: 10.3389/fendo.2014.00119
This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology.
Copyright © 2014 Janovsky, Rolim, Sá, Poyares, Tufik, Silva and Dib. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.